Drug application
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE)
Drugs@FDA ANDA 211595 · CIPLA
Key facts
| Drug name | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
|---|---|
| Active ingredients | DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE |
| Application type | ANDA |
| Application number | 211595 |
| Company | CIPLA |
| Dosage forms | TABLET, EXTENDED RELEASE, ORAL |
| Strength | 5MG;1GM |
| Marketing status | Prescription |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Apr 6, 2026 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.